Industry: Drug Manufacturing, Pharmaceuticals, Biotechnology
XTL Biopharmaceuticals Ltd. (“XTL”) is engaged in the acquisition, development and commercialization of therapeutics for the treatment of infectious diseases, with a focus on hepatitis C. XTL is developing XTL-2125 – a small molecule, non-nucleoside inhibitor of the hepatitis C virus polymerase. XTL-2125 is currently in a Phase 1 clinical trial in patients with chronic hepatitis C. XTL is also developing XTL-6865 – a combination of two monoclonal antibodies against the hepatitis C virus – presently in Phase 1 clinical trials in patients with chronic hepatitis C. XTL’s hepatitis C pipeline also includes several families of pre-clinical hepatitis C small molecule ( www.xtlbio.com )
XTL Biopharmaceuticals Ltd.
750 Lexington Avenue 20Th Floor
New York, New York 10022
USA
Tel: (212) 531-5960
Fax: (212) 531-5961